Mct8 (Slc16A2)-Specific Thyroid Hormone Cell Transporter Deficiency

2

Review clinical trials related to Mct8 (Slc16A2)-Specific Thyroid Hormone Cell Transporter Deficiency. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Available

Rescue of Infants With MCT8 Deficiency

Monocarboxylate Transporter 8 (MCT8) deficiency (that is also known as Allan-Herndon-Dudley syndrome) is a rare X-linked inherited disorder of brain development that causes severe intellectual disability and problems with movement. This condition, which occurs almost exclusively in males, disrupts development from before birth.

Trial details
Age: Up to 18Biological sex: MaleType: Expanded AccessSponsor: Roy E. Weiss, M.D.Updated: Dec 11, 2025Locations: 1
Eligibility criteria

Genetic Confirmation: Male fetus or fetuses (including monozygotic twin pregnanc... [+4]

Atrial fibrillation or other arrhythmias. [+2]

Status: Recruiting

The Myelin Disorders Biorepository Project

The Myelin Disorders Biorepository Project (MDBP) seeks to collect and analyze clinical data and biological samples from leukodystrophy patients worldwide to support ongoing and future research projects. The MDBP is one of the world's largest leukodystrophy biorepositories, having enrolled nearly 2,000 affected individuals since it was launched over a decade ago. Researchers working in the biorepository hope to use these materials to uncover new genetic etiologies for various leukodystrophies, develop biomarkers for use in future clinical trials, and better understand the natural history of these disorders. The knowledge gained from these efforts may help improve the diagnostic tools and treatment options available to patients in the future.

Participants needed: 12,000
Trial details
Biological sex: AllType: ObservationalSponsor: Children's Hospital of PhiladelphiaUpdated: Oct 23, 2025Locations: 23Duration: 10 Years
Eligibility criteria

Male or female of any age; [+3]

Established diagnosis at the time of referral that is not consistent with a gene... [+4]